Abstract The morphogenetic factor Sonic hedgehog (SHH) has been discovered as one of the masterplayers in cerebellar patterning and was subjected to intensive investigation during the last decade. During early postnatal development, this continuously secreted cholesterolmodified protein drives the expansion of the largest neuronal population of the brain, the granular cells. Moreover, it acts on Bergmann glia differentiation and would potentially affect Purkinje cells homeostasis at adult age. The cerebellar cortex constituted an ideal developmental model to dissect out the upstream mechanisms and downstream targets of this complex pathway. Its deep understanding discloses some of the mechanistic disorders underlying pediatric tumorigenesis, congenital ataxia, and mental retardation. Therapeutical use of its regulators has been consolidated on murine transgenic models and is now considered as a realistic human clinical application. Here, we will review the most recent advances made in the comprehensive understanding of SHH involvement in cerebellar development and pathology.
inhibition exerted on SMO is released, and this allows its accumulation in the cilia. SMO activates an inhibitory G protein Gαi that stops cAMP production [3] . The fulllength GLI3, no longer cleaved, becomes transcriptionally active together with GLI2, and both initiate a downstream activation of GLI1 [4, 5] . The target genes of the GLI factors are only partly identified. They belong to the cell cycle regulators and to the SHH pathway itself.
Specific Role of SHH in the Developing Cerebellum
The cerebellum is built up in successive waves of progenitors proliferation and migration throughout the embryonic and postnatal development. Most of the cerebellar cell types (Purkinje cells, Bergmann glia, astrocytes, interneurons, and neurons of the deep nuclei) arise from ventricular zone progenitors that migrate through the forming cortex during early embryogenesis. The cerebellar granular cells originate from a secondary germinal zone in the rostral rhombic lip [6] . These progenitors called cerebellar granular neuronal precursors (CGNPs) undergo a first wave of proliferation at E13,5 in the mouse. Then, from E17,5 on, they migrate over the nascent cerebellum to form the external granular layer (EGL), where their population massively expands. This proliferation phase peaks at P5-P8 and declines thereafter to stop at around P15 [7] . From about P8 on, CGNPs start extending processes and initiate their onwards migration. Their cell body closely apposed to the Bergmann glia fibers, they move through the growing network of the Purkinje cell dendrites in the molecular layer (ML) to reach the future internal granular layer (IGL). Their final neuronal differentiation is accomplished in the IGL about 3 weeks after birth.
The duration and intensity of the proliferation phase generating the pool of CGNPs is critical for the final shape and function of the cerebellum. SHH was discovered as the master player triggering the expansion of this population. Indeed, a putative involvement of SHH in cerebellum was first suspected from studies on the inhibition of cholesterol synthesis. As SHH needs to be cholesterol-modified to be active, this inhibition led to a defective SHH signaling causing abnormal cerebellar development [8] [9] [10] . In concordance, the human pathology Smith Lemli-Opitz syndrome, which is due to reduced cholesterol metabolism, is characterized by a hypoplastic cerebellum [11, 12] .
The critical mitogenic function of SHH was evidenced almost simultaneously by four different groups [13] [14] [15] [16] . From E17.5 on, SHH was shown to be continuously secreted from the Purkinje cells and to diffuse up to the EGL [13] . The outer EGL composed of proliferative CGNPs shows the highest expression of GLI1, read-out of the SHH pathway. These studies demonstrated the potent proliferative role of SHH on CGNPs using diverse combinations of in vitro and in vivo assays based on CGNPs cultures, slices, and/or explants and injection of inhibitory anti-SHH antibodies [13] [14] [15] . Among the already identified mitogens in the cerebellum (FGF-2, IGF-1, epidermal growth factor (EGF)), SHH turned out to clearly be the most potent mitogenic factor as it is solely able to trigger up to a 100-fold increase of CGNP proliferation in vitro [15] . SHH proliferative effect on CGNPs is restricted to the sole postnatal phase, as its abrogation (using a SMOdeleted conditional knock-out (KO)) does not affect CGNPs expansion until soon after birth [17] . Gli2 transcriptional activation is critical for this expansion, as its conditional deletion leads to CGNP proliferation failure and reduced size of the cerebellum [18] . SHH signaling was also shown to affect the Bergmann glia population. These cells together with the CGNPs express high levels of Ptc and Gli1 [13, 19] . SHH addition to cultured cerebellar explants promotes Bergmann glia differentiation [13] . In addition, the fibers of the Bergmann glia are malformed and irregular upon conditional mutation of Gli2 [17] . The exact role of SHH in Bergmann glia maturation and function remains presently unclear. These observations, however, indicate that SHH does not only contribute to the final number of mature granular cells by promoting their initial expansion but also by inducing the maturation of their migration support.
SHH overall expression profile in early postnatal stages is directly responsible for the final size and shape of the cerebellum. Indeed, several groups reported an unequal distribution of the protein along the Purkinje cell layer, especially confined to the regions where fissures form first [18, 20] . Finally, this was shown to determine the differential growth of the EGL ending in a defined size of folium. Absence of foliation was first demonstrated after conditional deletion of SHH or injection of blocking anti-SHH antibodies [13, 20] . SHH-P1 mutants overexpressing SHH in the Purkinje cells presented with a larger cerebellum, and an extralobule could even be formed upon further increase of SHH activity in the SHH-P1; Ptc+/− mouse [17] . In conclusion, SHH, although dispensable for determination of folium position, is required for full lobe extent.
Effectors of the SHH Pathway
SHH mediates CGNPs proliferation through the induction and repression of cell cycle regulators genes. Some studies attempted to have a comprehensive view of the genes affected during CGNPs proliferation, with or without addition of SHH [21, 22] , and some promising candidates of the identified cascade have been tested for their impact. These include the cyclin family members, cyclin A2, B1, D1 and D2, the Forkhead transcription factor FoxM1, the growth factor IGF-2, the proto-concogene Nmyc, and Bmi-1 [16, 23, 24] . In a feedback loop, SHH also triggers the transcription of Ptc and Gli1 and downregulates Gli3.
Cyclin D1 and D2 are known to regulate the G1/S phase transition. These are direct transcriptional targets of SHH, induced rapidly [16] . Absence of Cyclin D1 expression in the cerebellum decreases the number of cycling CGNPs [25] . In contrast to Cyclin D1, highly expressed in the EGL from E17 on, Cyclin D2 expression arises later in the outer EGL at around P6. Its deletion results in a mild hypoplastic cerebellum [26] . Altogether, deletion of both genes has a dramatic hypoplastic effect on the cerebellar development [27] . SHH modulates the G2/M transition through induction of the Forkheadd transcription factor FoxM1. It regulates mitotic entry through transcription of Cyclin B1 and Cdc25b. Its deletion in CGNPs produces defects in spindle assembly and chromosome segregation [28] .
Transcriptional induction by SHH requires the bHLH transcriptional activator N-Myc from the Myc/Max/Mad family [16, 22] . N-myc and Mad form heterodimers with Max prior binding to DNA. In the cerebellum, N-Myc expression peaks in the proliferative CGNPs upon SHH stimulation. Conditional disruption of the N-myc gene in the brain impairs CGNPs proliferation [29] , and its overexpression is sufficient to boost CGNP proliferation [30] . Mad3, another bHLH transcription factor, was also identified as a target gene of SHH [31] . Expressed in CGNPs during their phase of expansion, it dimerizes with Max and recruits the corepressor Sin3 to inhibit DNA transcription. Mad3 overexpression is by itself sufficient to trigger CGNP proliferation [31] .
The polycomb group gene Bmi-1 expression peaks in the CGNPs during their proliferation phase. Its deletion impairs their survival and expansion leading to a depleted IGL. Bmi-1 was demonstrated in culture as a downstream target and effector of SHH signal transduction [32] .
Regulators of the SHH Pathway
It is, however, surprising that no decay of SHH expression is detected when the pool of CGNPs has been fully generated. The SHH level remains quite elevated even at mature adult stage [33] . The biological meaning of this high expression level has not been elucidated until now. As the modulation of SHH concentration strongly influences the final shape of the cerebellum [17] , a tight regulation system seems required to control its biological impact. Some of the molecules involved in the tuning of the SHH mitogenic signal have been discovered, and their role, supportive or inhibitory, is partly understood. The mechanisms are extremely diversified and act at multiple levels. They can modulate the quantity of SHH protein by acting at the transcriptional level or interfere extracellularly or intracellularly with the SHH-dependent pathways (Fig. 2) .
Cooperative Regulators
The positive regulators are synergistic to the mitogenic effect of SHH. This generally happens in the outer EGL to maintain a high number of continuously dividing CGNPs.
Chemokines and Growth Factors
The synergistic role of the chemoattractant SDF-1α and of its receptor CXCR4 has been substantiated [34] . SDF-1α has in fact a dual function: it attracts the CGNPs to the outer EGL and promotes in vitro a 50% increase of the SHH mitogenic effect. This synergy is effective through the CXCR4-mediated activation of the G-protein Gαi, that would lead to a downstream decrease of cAMP [34] .
Among fetal mitogens, IGF-2 has been reported as an efficient enhancer of SHH on CGNPs [35] . In cultured CGNPs, the presence of the recombinant IGF-2 further increases SHH stimulation by 2.2-fold [15] . The presence of IGF-2 significantly enhances Gli1 and cyclin D1 expression induced by SHH but not N-myc expression [35] . Altogether, the data clearly establishes IGF-2 as an important positive regulator of some SHH effects on CGNPs.
It has not yet been established which receptor (IGF-1R or IGF-2R) mediates the synergistic effect of IGF-2 on the SHH pathway. Whether IGF-1 can also potentiate SHH has not been determined either. IGF-2 synergistic effect would be mediated through the insulin receptor substrate 1 (IRS1) [36] . IGF-2 binding to IGF-1R leads to phosphorylation of IRS1 that finally activates the PI3K pathway. Knock-down experiments have shown that IRS1 activity is required for CGNP proliferation in slice explants and dissociated CGNPs cultures. IRS1 overexpression can maintain CGNP proliferation in the absence of SHH. SHH treatment upregulates IRS1 by stabilization of the protein rather than by transcription. Given the known proliferative effect of IGF1 on CGNPs and the fact that IRS1 is essential for IGFmediated proliferation in other cell types, these results identify IRS1 as a new effector of SHH in CGNP proliferation. They also provide evidence for interactions between SHH and other mitogenic pathways. In this respect, very recently published results showed experimental evidence for the first time of an interaction between the SHH and the mTOR pathways. mTOR, directly or indirectly through the phosphorylation of S6, stimulates the phosphorylation of IRS1 which leads to its degradation [37] . In cultured CGNPs, the inhibition of SHH signaling through cyclopamine decreases IRS1 protein levels. This effect is prevented by rapamycin, an inhibitor of the mTOR: Raptor complex [36] . However, the detailed mechanisms involved in this SHH-mediated mTOR inhibition will require further investigations.
Extra Cellular Matrix
The cellular environment, namely the extracellular matrix (ECM), is intensively remodeled throughout cerebellar 
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Antagonistic Regulators
On the other hand, the activity due to the persistent SHH high protein level must be tuned down by some negative regulators to favor CGNPs cell cycle exit and the onset of differentiation. Such antagonistic agents preferentially target the deep inner EGL.
ECM and ECM Remodeling Agents
Increasing levels of vitronectin and of its receptor, the integrin subunit αv, are found in the deep inner EGL. Vitronectin binds directly to SHH and has been shown to stop SHH-mediated mitosis by inducing the phosphorylation of cAMP response element-binding (CREB) [43] , known to associate with Gli1 and the adaptor p300 to modulate SHH signaling. A similar inhibitory effect was observed for the ECM glycoprotein fibronectin [43] .
The ECM fluctuates rapidly thanks to the involvement of proteases and their inhibitors. The serine-protease inhibitor Protease Nexin-1 (PN-1) is secreted by the Purkinje cell layer with a peak of expression during the proliferation temporal window. It was recently shown that its binding to the low density lipoprotein receptor-related protein (LRP) efficiently antagonizes SHH-induced mitosis in cultured CGNPs. Disruption of the PN-1 gene in vivo leads to overactivation of the SHH pathway and expansion of defined lobes [44] . The downstream mechanism has not yet been characterized but could rely on a competitive binding between PN-1, SHH, and the LRP receptor. Indeed, SHH binding to LRP and subsequent endocytosis has been evidenced using different cell lines [45] . Moreover, binding of SHH to LRP-2 has been established, and mice lacking LRP-2 (also named Megalin or gp330) exhibit numerous phenotypical similarities with the SHH-null mutant [46] .
Growth Factors
It is well established that increasing cAMP levels or protein kinase A activity stops SHH transduction [4] . The neuropeptide pituitary adenylate-cyclase activating polypeptide (PACAP) has been identified as one of the negative regulators of SHH pathway acting upstream of the PKA kinase [48] . Its binding to the G-coupled receptor PAC1 is considered to trigger an increase in cAMP leading to the final phosphorylation of the cAMP responsive transcription factor CREB. PACAP knock-out mice exhibit enlarged EGL coupled with overactivated SHH pathway [48] .
Furthermore, SHH is inactivated by a growth-promoting mitogen, FGF-2. On its own, this growth factor stimulates CGNPs proliferation [15] . Intriguingly, its combination with SHH renders its proliferative effect unoperative and triggers CGNP differentiation [15, 49] The novel EGF-responsive gene REN KCTD11 , that has been discovered to be a prodifferentiating and growth arrest factor in the developing nervous system, accumulates in the postmitotic granular cells of the inner EGL [53] . In culture experiments, these authors demonstrate that ectopic expression of REN KCTD11 leads to decayed proliferation in CGNPs, associated with a decreased activity of GLI1 and GLI2. Its loss of function supports SHH-dependant proliferation. REN KCTD11 would act by regulating the cyclindependent kinase inhibitor p27/Kip1 [54] .
The developmental protein Numb also appears to be involved in SHH-mediated proliferation and signaling. This protein, critical for asymetric cell division, assigns cell polarity by accumulating in the newly generated daughter cells. Numb-deficient mice present with a cerebellar developmental phenotype marked by an enlarged EGL, where CGNPS are unable to start differentiation [55] . Di Marcotullio and collaborators [56] showed that Numb directly affects SHH signaling by promoting GLI1 degradation. Its effect first requires recruitment and complexation with the HECT-type E3 ligase Itch. This allows polyubiquitination of GLI1 that can no longer activate transcription in the nucleus [56] .
SHH in Disease
SHH and Medulloblastoma
Deregulation of the SHH pathway is responsible for abnormal cerebellar proliferation, which results in one of the most common and most aggressive childhood brain tumors, medulloblastomas [57] . These highly malignant tumors belong to the subclass of primitive neuroectodermal tumors which account for about 20-30% of all childhood brain tumors [58] . A combination of surgery with radiation and chemotherapy represents the classical treatments, but the lack of accuracy often results in cognitive and neuroendocrine deficits, and tumors reoccur rather often.
Medulloblastomas have long been thought to arise from an exceeding proliferation of the CGNPs located in the EGL. However, some groups then reported expression in the tumors of markers typical from the remnant stem cells of the underlying IVth ventricle [59] . The medulloblastomas were also shown to contain multipotent neural stem cells that could be driven to the neuronal or glial lineage [60] . The identification of the "cell of origin" transformed by SHH oversignaling has been recently and simultaneously addressed by Yang et al. and Schüller et al. They have conditionally overactivated SHH pathway in lineagerestricted CGNPs and sought for their potential susceptibility to tumor formation [61, 62] .
The first evidence of SHH involvement in medulloblastoma came from the characterization of the Gorlin syndrome, also known as basal cell nevus syndrome [63] . Gorlin patients carry germline mutations of the PTC receptor leading to its inactivation and subsequent SHH overactivation. Ten per cent of these patients develop medulloblastomas. Many reports described several other sporadic mutations affecting the SHH pathway, including, apart from PTC (in 10% of the cases), SMO and the intracytoplasmic inhibitor of the SHH pathway suppressorof-fused (SUFU) [64] [65] [66] . The second evidence of the direct implication of SHH in medulloblastoma biology came from the murine experimental models. Targeted overexpression of SHH in neural progenitors of the cerebellum in newborn mice or in utero is sufficient to induce medulloblastoma [67, 68] . Moreover, inactivation of Ptc and constitutive activation of Smo in genetically engineered mice is sufficient to trigger tumor formation that faithfully recapitulates the biology of human tumors [65, [69] [70] [71] . The Ptc heterozygous mutant mice develop medulloblastomas ( Fig. 3 ) with an incidence of about 20% within 1 year [69] . Gli1 is involved in the transformation as the double mutants Gli1 −/−, Ptc+/− develop medulloblastomas at lower frequency than Ptc+/− mice [72] . The tumor frequency associated with the Ptc mutation increases dramatically in the p53 null background, exceeding 95% at 3 months of age [73] . Similarly Sufu is a more potent tumor suppressor. Still, the incidence of these mutations is quite low in humans and does not account for the general SHH deregulation affecting most of the tumors, for more than 30% of them exhibit overexpression of the target gene Gli1 [75] . Given also the poor penetrance of tumor formation in the mouse models, such as the Ptc+/− mutant, there must be additional causative factors at the origin of tumorigenesis. A growing number of reports identify some of these.
IGF-2 is often upregulated in the human medulloblastomas of the desmoplastic type [76] . Its requirement in SHHrelated oncogenesis was evidenced by the fact that its genetic deletion blocks medulloblastoma formation in the Ptc+/− mutant mice [77] . IGF-2 binding to IGF-1R leads to final activation of PKB. Coexpression through retroviral injection of Shh/Igf-2 or Shh/PKB in neuronal progenitors drove increased formation of medulloblastomas with an efficiency of more than 2-and 3-fold, respectively, compared with SHH alone [78] . The PI3Kinase pathway was found to stabilize N-Myc through inhibition of its GSK-3β-mediated phosphorylation [79] . Although retroviral coexpression of N-Myc and SHH in neural progenitors reinforces medulloblastoma induction, N-myc ectopic expression, alone or combined with IGF pathway members or Gli1, produces no oncogenic effect [80] . This indicates that SHH needs additional unidentified factors to generate the tumor. In this respect, it is interesting to note that some of the molecules identified in association with medulloblastomas are among the effectors or cooperative regulators of the SHH pathway mentioned earlier.
A recent publication [81] strengthened the involvement of SHH pathway in medulloblastoma neoplasia. Over a group of 31 medulloblastomas biopsies, the authors identified a marked increase of GLI1 expression in half of them and split the group in high GLI1-and low GLI1-expressing tumor subsets. After a microRNA high-throughput expression profile analysis, they evidenced that the high GLI1 tumor subset showed a poor level of microRNAs targeting SMO and GLI1 3′ UTRs. Interestingly, such miRNAs are transcribed in the chromosome 17p arm, a region frequently deleted in 40% of medulloblastomas. As medulloblastomas very rarely exhibit mutations of GLI1 or SMO, their overactivation could be attributed to mutation(s) resulting in repression of miRNA expression. These transcriptional regulators have also an inhibiting effect during normal postnatal development. Their ectopic expression reduces SHH-induced proliferation [81] .
P53, HIC1, and REN
KCD11 , all known to cooperate normally with the SHH pathway, are affected as well by the 17p chromosom arm deletion commonly found in medulloblastomas. In mice, their deletion strengthens the effect of the Ptc heterozygous deletion [73, [82] [83] [84] .
The comprehension and use of the physiological developmental SHH antagonists that have been or will be characterized will undoubtedly condition future therapeutical strategies (Table 1) .
Several groups have undergone preclinical trial in this direction [85, [86] [87] [88] [89] [90] . The addition of FGF stops the growth of CGNPs extracted from a mouse model of medulloblastoma [49] . In addition, FGF stops the growth of human medulloblastoma cell lines [91] and human medulloblastoma xenografts injected in nude mice [92] .
SHH and Congenital Ataxia
Primary cilia are determinant for SHH signal transduction. The SHH intramembranous transducer Smo concentrates in the cilia when activated by SHH, and PTC meanwhile leaves the cilia compartment [93] . In the cerebellum, disrupting primary cilia formation and maintenance by deleting Kif3a and IFT88 abolished SHH-mediated CGNPs proliferation [94, 95] . Interestingly, mutations of the genes Unpublished personal data. Similar data have been published earlier (Goodrich et al. [69] ). Cb cerebellum, Tel telencephalon involved in the assembly and stability of cilia have been reported in the Joubert Syndrome [96] . This recessively hereditary disease is marked by a congenital ataxia and mental retardation linked to malformations of the brainstem, cerebellum, and cerebellar peduncles [97] . SHH is also suspected to play a role in a second congenital ataxia syndrome termed the Dandy-Walker malformation. In this case, chromosome regions encompassing Zic1 and Zic4 coding zones are deleted. Such Zinc finger transcription factors are thought to modulate SHH signaling pathway in the developing cerebellum [98] , although the precise mechanisms of such regulation are still under investigation.
SHH in Down Syndrome
The Down Syndrome, also called trisomy 21, is marked by the inheritance of a supplementary chromosome 21 due to its improper disjunction during meiosis. Interestingly, Latash and Corcos [99] noted a reduction of the granular cell layer volume in the cerebellum of the patients with Down Syndrome accompanied by hypotonia and finemotor control impairment [99] . A mouse transgenic model of Down Syndrome Ts65Dn could phenocopy the reduction of CGNPs, resulting from an insufficient mitotic rate. In addition, the granular cells of the transgenic mouse exhibited reduced sensitivity to SHH [100, 101] . Intraventricular infusion of recombinant SHH significantly rescued the reduced granular volume observed in the Ts65Dn.
Conclusions
In summary, the well-defined structure and developmental steps characterizing the cerebellum provided additional information and perspectives on the impact of SHH in the nervous system. In the future, it will be interesting to see whether studies in this structure will allow further important contributions. For example, the meaning of the persistent high expression of SHH in the adult cerebellum remains an intriguing issue. Is the biological activity of SHH strongly reduced or even masked by antagonists in the adult? Does discrete removal of such inhibition lead to localized impact of SHH in mature brain structures as observed in the adult rat nervous system [19] ? Would such focalized activity influence the proliferation or fate of precursor cells as recently described in the mouse optic nerve [102] ? Would it rather contribute to circuit, respectively synaptic plasticity by acting as axonal chemoattractant as shown in the midline axon guidance [103] or by enhancing retinoic acid induced neurite outgrowth as evidenced in a subpopulation of dorsal ganglia neurons [104] ? Given the knowledge presently available, the cerebellum could be an appropriate in vivo model to better define distinct functions of SHH in the adult nervous system. 
